Role of HbA1c in TB Symptom Severity, Treatment Success, and Risk Management
At baseline, 40% of participants had euglycemic HbA1c levels, 35% had prediabetes, and 24% had diabetes, with improvements observed after three months of TB treatment. Persistent hyperglycemia was associated with a non-significant increase in unfavorable outcomes, but transient hyperglycemia doubled the risk (aIRR: 2.07; 95% CI: 1.04-4.15; P = 0.040). Patients with hyperglycemia who received diabetes treatment achieved better clinical outcomes, emphasizing the importance of timely intervention. Monitoring HbA1c trajectories during early TB treatment can help identify individuals at higher risk for unfavorable outcomes.[1] Data from three teaching hospitals in Taiwan (2005–2010) analyzed 1,473 culture-positive pulmonary TB patients (705 with diabetes, 768 without), excluding those with transient hyperglycemia at the start of treatment. Diabetic patients were less likely to achieve treatment success and faced higher risks of death and being lost-to-follow-up, with symptoms such as cough